相似文献
1
Generating protective immunity against genital herpes.
Trends Immunol. 2013 Oct;34(10):487-94. doi: 10.1016/j.it.2013.08.001. Epub 2013 Sep 3.
2
Multivalent DNA vaccine protects against genital herpes by T-cell immune induction in vaginal mucosa.
Antiviral Res. 2020 May;177:104755. doi: 10.1016/j.antiviral.2020.104755. Epub 2020 Feb 26.
3
Novel Role for Interleukin-17 in Enhancing Type 1 Helper T Cell Immunity in the Female Genital Tract following Mucosal Herpes Simplex Virus 2 Vaccination.
J Virol. 2017 Nov 14;91(23). doi: 10.1128/JVI.01234-17. Print 2017 Dec 1.
4
A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens.
J Virol. 2015 Aug;89(16):8497-509. doi: 10.1128/JVI.01089-15. Epub 2015 Jun 3.
5
Vaccines to prevent genital herpes.
Transl Res. 2020 Jun;220:138-152. doi: 10.1016/j.trsl.2020.03.004. Epub 2020 Mar 16.
6
A vaccine strategy that protects against genital herpes by establishing local memory T cells.
Nature. 2012 Nov 15;491(7424):463-7. doi: 10.1038/nature11522. Epub 2012 Oct 17.
7
Immunization against genital herpes with a vaccine virus that has defects in productive and latent infection.
Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6994-8. doi: 10.1073/pnas.96.12.6994.
8
Nasal and skin delivery of IC31(®)-adjuvanted recombinant HSV-2 gD protein confers protection against genital herpes.
Vaccine. 2012 Jun 19;30(29):4361-8. doi: 10.1016/j.vaccine.2012.02.019.
9
Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group.
JAMA. 1999 Jul 28;282(4):331-40. doi: 10.1001/jama.282.4.331.
10
Estradiol Enhances Antiviral CD4 Tissue-Resident Memory T Cell Responses following Mucosal Herpes Simplex Virus 2 Vaccination through an IL-17-Mediated Pathway.
J Virol. 2020 Dec 9;95(1). doi: 10.1128/JVI.01206-20.
引用本文的文献
1
Genital herpes shedding episodes associate with alterations in the spatial organization and activation of mucosal immune cells.
bioRxiv. 2025 Jun 27:2025.06.24.661157. doi: 10.1101/2025.06.24.661157.
2
Small Animal Models to Study Herpes Simplex Virus Infections.
Viruses. 2024 Jun 27;16(7):1037. doi: 10.3390/v16071037.
3
Seroprevalence and Vaginal Shedding of Herpes Simplex Virus Type 2 in Pregnant Adolescents and Young Women from Morelos, Mexico.
Viruses. 2023 May 8;15(5):1122. doi: 10.3390/v15051122.
4
Cell-to-cell spread inhibiting antibodies constitute a correlate of protection against herpes simplex virus type 1 reactivations: A retrospective study.
Front Immunol. 2023 Mar 16;14:1143870. doi: 10.3389/fimmu.2023.1143870. eCollection 2023.
5
Mucosal viral infection induces a regulatory T cell activation phenotype distinct from tissue residency in mouse and human tissues.
Mucosal Immunol. 2022 May;15(5):1012-1027. doi: 10.1038/s41385-022-00542-7. Epub 2022 Jul 11.
6
A sustained type I IFN-neutrophil-IL-18 axis drives pathology during mucosal viral infection.
Elife. 2021 May 28;10:e65762. doi: 10.7554/eLife.65762.
7
Circulating immunity protects the female reproductive tract from infection.
Proc Natl Acad Sci U S A. 2021 May 25;118(21). doi: 10.1073/pnas.2104407118.
8
TRIM26 Facilitates HSV-2 Infection by Downregulating Antiviral Responses through the IRF3 Pathway.
Viruses. 2021 Jan 6;13(1):70. doi: 10.3390/v13010070.
9
Use of the Guinea pig model of genital herpes to evaluate vaccines and antivirals: Review.
Antiviral Res. 2020 Aug;180:104821. doi: 10.1016/j.antiviral.2020.104821. Epub 2020 Jun 13.
10
T cell response kinetics determines neuroinfection outcomes during murine HSV infection.
JCI Insight. 2020 Mar 12;5(5):134258. doi: 10.1172/jci.insight.134258.
本文引用的文献
1
Immune surveillance by CD8αα+ skin-resident T cells in human herpes virus infection.
Nature. 2013 May 23;497(7450):494-7. doi: 10.1038/nature12110. Epub 2013 May 8.
2
Rapid localized spread and immunologic containment define Herpes simplex virus-2 reactivation in the human genital tract.
Elife. 2013 Apr 16;2:e00288. doi: 10.7554/eLife.00288.
3
Rapid host immune response and viral dynamics in herpes simplex virus-2 infection.
Nat Med. 2013 Mar;19(3):280-90. doi: 10.1038/nm.3103.
4
Herpes simplex virus 1 infection induces activation and subsequent inhibition of the IFI16 and NLRP3 inflammasomes.
J Virol. 2013 May;87(9):5005-18. doi: 10.1128/JVI.00082-13. Epub 2013 Feb 20.
5
The herpes simplex virus 1-encoded envelope glycoprotein B activates NF-κB through the Toll-like receptor 2 and MyD88/TRAF6-dependent signaling pathway.
PLoS One. 2013;8(1):e54586. doi: 10.1371/journal.pone.0054586. Epub 2013 Jan 28.
6
An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs.
J Virol. 2013 Apr;87(7):3930-42. doi: 10.1128/JVI.02745-12. Epub 2013 Jan 30.
7
Broadly neutralizing antiviral antibodies.
Annu Rev Immunol. 2013;31:705-42. doi: 10.1146/annurev-immunol-032712-095916. Epub 2013 Jan 16.
8
Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway.
Science. 2013 Feb 15;339(6121):786-91. doi: 10.1126/science.1232458. Epub 2012 Dec 20.
9
Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA.
Science. 2013 Feb 15;339(6121):826-30. doi: 10.1126/science.1229963. Epub 2012 Dec 20.
10
HSV-2 vaccine: current state and insights into development of a vaccine that targets genital mucosal protection.
Microb Pathog. 2013 May;58:45-54. doi: 10.1016/j.micpath.2012.11.001. Epub 2012 Nov 15.
Zotero 插件